Early oral Feeding is Safe and Useful after Rectosigmoid Resection with Anastomosis During Cytoreductive Surgery for Primary Ovarian Cancer

Kazuyoshi Kato (kazuyosikato@gmail.com)  
Cancer Institute Hospital       https://orcid.org/0000-0001-7622-8253

Kohei Omatsu  
Cancer Institute Hospital

Sanshiro Okamoto  
Cancer Institute Hospital

Maki Matoda  
Cancer Institute Hospital

Hidetaka Nomura  
Cancer Institute Hospital

Terumi Tanigawa  
Cancer Institute Hospital

Yoichi Aoki  
Cancer Institute Hospital

Mayu Yunokawa  
Cancer Institute Hospital

Hiroyuki Kanao  
Cancer Institute Hospital

Research

Keywords: Ovarian cancer, Rectosigmoid resection, Early oral feeding, Postoperative morbidity, Postoperative hospital stay

DOI: https://doi.org/10.21203/rs.3.rs-127807/v1

License: ☑️ This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background

The aim of this study was to investigate the safety and clinical usefulness of early oral feeding (EOF) after rectosigmoid resection with anastomosis for the treatment of primary ovarian cancer.

Methods

We performed a retrospective review of all consecutive patients who had undergone rectosigmoid resection with anastomosis for primary ovarian, tubal, or peritoneal cancer during a 7-year period. Patient-related, disease-related, and surgery-related data including the incidence of anastomotic leakage and postoperative hospital stay were collected. EOF was introduced as a postoperative oral feeding protocol during the middle of the study period. Before the introduction of EOF, conventional oral feeding (COF) had been used.

Results

Two hundred and one patients who underwent rectosigmoid resection with anastomosis, comprised of 95 patients in the COF group and 106 patients in the EOF group, were included in this study. The median number of postoperative days until the start of diet intake was 5 (range: 2–8) in the COF group and 2 (range: 2–8) in the EOF group ($P < 0.001$). Postoperative morbidity was equivalent between the groups. The incidence of anastomotic leakage was similar (1%) in both groups. The median length of the postoperative hospital stay was reduced by 6 days for the EOF group: 17 (range: 9–67) days for the COF group versus 11 (8–49) days for the EOF group ($P < 0.001$).

Conclusion

EOF provides a significant reduction in the length of the postoperative hospital stay without an increased complication risk after rectosigmoid resection with anastomosis as a part of cytoreductive surgery for primary ovarian cancer.

Background

A maximal surgical effort to obtain a macroscopic complete resection has been confirmed to improve survival among patients with advanced ovarian cancer [1–3]. An en bloc resection of the rectosigmoid together with the uterus, tubes/ovaries, and the pelvic tumors, also known as modified posterior pelvic exenteration or radical oophorectomy, is one of the most frequently performed types of surgical...
procedures during cytoreductive surgery for advanced ovarian cancer [4–7]. Anastomotic leakage remains a life-threatening potential complication of rectosigmoid resections despite advances in surgical techniques and medical instrumentation [8, 9]. As cytoreductive surgery aimed at complete resection requires the removal of multiple organs and the resection of extensive amounts of the peritoneum, it is usually complicated and invasive. Rectosigmoid resection with anastomosis is regarded as the most complicated surgical procedure among the various procedures that might be required during cytoreductive surgery for advanced ovarian cancer, including diaphragmatic resection, splenectomy and hepatectomy as well as large and small bowel resections [10].

Enhanced Recovery After Surgery (ERAS) has been developed to accelerate recovery by attenuating the stress response. Previous studies have demonstrated that ERAS perioperative care affects neural, metabolic and other organ functions beneficially [11, 12]. Consequently, this multimodal approach has been shown to shorten the length of the hospital stay, reduce the surgical stress response, decrease morbidity, and expedite recovery. As part of ERAS programs, there has recently been a move toward early feeding regimens postoperatively. The benefits of early postoperative oral feeding (EOF) include a faster recovery of bowel function and lower rates of infectious complications [13]. In the field of gynecologic surgery, it has been demonstrated that implementation of as many ERAS elements as possible is associated with a decrease in the length of the hospital stay without increasing the postoperative complication rate or mortality [14, 15]. As high-complexity surgery is more frequently performed for primary ovarian cancer surgery than for colorectal or ordinary gynecologic surgery, whether EOF is also safe for ovarian cancer patients who undergo rectosigmoid resection with anastomosis as a part of cytoreductive surgery remains unknown. We evaluated the impact of EOF on postoperative outcomes, including postoperative hospital stay, following rectosigmoid resection.

Methods

1. Patient selection

All consecutive patients who underwent rectosigmoid resection with anastomosis as part of cytoreductive surgery for primary ovarian, tubal, or peritoneal cancer at the Cancer Institute Hospital, Japan, between April 2012 and March 2019 were evaluated for inclusion in this study. In April 2012, well-trained gynecologic oncologists started to perform cytoreductive surgery, including small and large bowel resection with anastomoses, stoma creation, diaphragm stripping/resection with liver mobilization, and splenectomy with distal pancreatectomy, at our institution. The patients’ medical records were reviewed, and patient-related, disease-related, and surgery-related data were retrieved. These data included the patient’s age, performance status, medical history, primary site of disease, clinical stage, timing of surgery (up-front surgery or interval debulking surgery), preoperative laboratory values including the serum levels of hemoglobin and albumin, surgical procedures, residual disease, operative time, estimated blood loss, intraoperative blood transfusion, final histopathologic results, diet resumption, length of postoperative hospital stay, duration from surgery until the start of postoperative chemotherapy, and morbidity within 60 days after surgery. The complexity of the surgical procedures performed was stratified in accordance
with the previously advocated surgical complexity score (SCS) system into 3 groups (low, moderate, and high) [10]. Perioperative complications were registered and classified according to the Clavien–Dindo classification [16]. Preoperative bowel preparation was identical throughout the study period. Patients were given 180 mL of magnesium citrate on the day before surgery. Oral antibiotic bowel preparation was not used and prophylactic IV antibiotic therapy with cephalosporin was administered immediately before and during surgery in the current series. Since the middle of this study period, we have routinely utilized a transanal drainage tube (TDT) after rectosigmoid resection with anastomosis for patients with ovarian cancer to prevent anastomotic leakage [17]. This study protocol was approved by the Institutional Review Board of the Cancer Institute Hospital.

2. Timing of postoperative oral feeding and discharge

EOF after rectosigmoid resection with anastomosis was introduced at our hospital in September 2016. Patients in the EOF group began to drink water and/or tea on postoperative day (POD) 1. If these liquids were well tolerated, they advanced to a semisolid diet on POD 2 and to a regular diet within the next 2 to 3 days. Before the introduction of EOF, postoperative oral feeding had been managed using a conventional methodology. Patients in the conventional oral feeding (COF) group were managed with nothing by mouth until postoperative flatus was noted. Thereafter, they were allowed to drink water. If the water was tolerated, a liquid diet was given. They then advanced to a regular diet within the next 5 to 7 days. The durations of oral feeding prohibition in the patients who underwent a splenectomy combined with a distal pancreatectomy to achieve complete cytoreduction depended on the grade of pancreatic fistula. We placed a peripancreatic drain into the left subdiaphragmatic space in all the patients who underwent a splenectomy with a distal pancreatectomy for the diagnosis and management of pancreatic fistula [18]. Diet intake was started after the pancreatic fistula was confirmed to be resolved.

The criteria for discharge were as follows; whether the patient could eat a regular diet, walk for herself, make a living by herself, and get ready for postoperative chemotherapy. Gynecologic oncologists in our institution checked her conditions and talked the timing of discharge from hospital with her and her family.

3. Statistical analyses

Statistical analyses were performed using the Mann-Whitney U test for continuous variables and the chi square test or the Fisher exact test for categorical variables. A value of $P < 0.05$ was considered statistically significant.

Results

During this study period, 202 patients underwent rectosigmoid resection as part of cytoreductive surgery for primary ovarian, tubal, or peritoneal cancer at the time of initial therapy. One patient who underwent a Hartmann's procedure without colorectal anastomosis was excluded from this study. Finally, 201 patients who underwent rectosigmoid resection with anastomosis were evaluated in the current series. The
baseline characteristics of both the COF (n = 95) and the EOF (n = 106) groups were similar (Table 1). No differences were found between the two groups according to the surgical variables (Table 2). In addition to rectosigmoid resection, 21 patients (22%) in the COF group and 26 patients (25%) in the EOF group underwent one or more intestinal resection(s). Fifty-seven patients (60%) in the COF group and 60 patients (57%) in the EOF group underwent upper abdominal surgery including diaphragmatic stripping/resection and splenectomy with distal pancreatectomy. A diverting ileostomy was created in 10 patients (11%) in the COF group and 6 patients (6%) in the EOF group (Fig. 1). The creation of the diverting ileostomy during cytoreductive surgery was determined by the gynecologic oncologists according to the perceived risk of anastomotic leakage in a case-by-case manner. The reasons for the stoma creation were as follows: (1) the condition that a rescue stoma had been already created before cytoreductive surgery as the management of colorectal obstruction in 3 patients; (2) intestinal edema because of serious loss of blood and a large quantity of transfused blood in 8 patients; (3) a very low colorectal anastomosis at 1.5–2 cm from the anal verge in 2 patients; (4) the occurrence of a fissure on the colonic wall during colorectal anastomosis using the circular stapling device in 1 patient; and (5) the presence of poorly controlled diabetes mellitus in 2 patients.

Table 1

Patient and tumor characteristics
|                                | COF group (n=95) | EOF group (n=106) |
|--------------------------------|------------------|-------------------|
| Age, median (range), (years)   | 62 (30–82)       | 60 (33–80)       |
| BMI, median (range), (kg/m²)   | 20.9 (13.8–33.0) | 20.4 (14.0–32.6) |
| Presence of comorbidities, n (%) |                  |                   |
| Diabetes mellitus              | 7 (7)            | 8 (7)            |
| Hypertension                   | 22 (23)          | 22 (20)          |
| ASA score, n (%)               |                  |                   |
| 1                              | 33 (35)          | 30 (28)          |
| 2                              | 31 (33)          | 37 (35)          |
| 3                              | 30 (32)          | 37 (35)          |
| 4                              | 1 (1)            | 2 (2)            |
| Preoperative Hb, median (range), (g/dL) | 11.1 (8.2–15.0) | 11.6 (8.6–15.0) |
| Preoperative Alb, median (range), (g/dL) | 4.0 (1.9–5.0)   | 4.0 (2.0–4.7)   |
| Diagnosis, n (%)               |                  |                   |
| Ovarian cancer                 | 86 (91)          | 94 (89)          |
| Tubal cancer                   | 4 (4)            | 5 (5)            |
| Peritoneal cancer              | 5 (5)            | 7 (7)            |
| Clinical stage, n (%)          |                  |                   |
| I                              | 4 (4)            | 6 (6)            |
| IIB                            | 12 (13)          | 11 (10)          |
| IIIA                           | 5 (5)            | 4 (4)            |
| IIIB                           | 7 (7)            | 7 (7)            |
| IIIC                           | 44 (46)          | 48 (45)          |
| IVA                            | 1 (1)            | 4 (4)            |
| IVB                            | 22 (23)          | 26 (25)          |
| Histology, n (%)               |                  |                   |
| Serous                         | 65 (68)          | 71 (67)          |
| Clear cell                     | 12 (13)          | 19 (18)          |
| Endometrioid                   | 11 (12)          | 12 (11)          |
| Mucinous                       | 3 (3)            | 1 (1)            |
| Others | 4 (4) | 3 (3) |
|--------|-------|-------|
| COF, conventional oral feeding; EOF, early oral feeding; BMI, body mass index; ASA, American Society of Anesthesiologists; Hb, hemoglobin; Alb, albumin. |

Table 2

Surgical variables and postoperative complications
|                                | COF group (n=95) | EOF group (n=106) | P value |
|--------------------------------|------------------|-------------------|---------|
| **Timing of cytoreductive surgery** |                  |                   |         |
| Up-front, n (%)                | 48 (51)          | 53 (50)           | 0.941   |
| Interval, n (%)                | 47 (49)          | 53 (50)           |         |
| **Surgical complexity score**  |                  |                   |         |
| Intermediate, n (%)            | 41 (43)          | 40 (38)           | 0.434   |
| High, n (%)                    | 54 (57)          | 66 (62)           |         |
| **Surgical procedures performed in addition to MPPE** | |                   |         |
| Splenectomy + distal pancreatectomy | 3 (3)<sup>b</sup> | 6 (6)<sup>c</sup> | 0.608   |
| Small and/or large bowel resection(s) | 21 (22)<sup>b</sup> | 26 (25)<sup>c</sup> |         |
| **Residual tumor after surgery, n (%)** | |                   |         |
| 0                              | 82 (86)          | 99 (93)           | 0.242   |
| 0<, <1 cm                      | 8 (8)            | 4 (4)             |         |
| ≥1 cm                          | 5 (5)            | 3 (3)             |         |
| **Operative time, median (range), (min)** | 411 (222–689) | 389 (196–719) | 0.125   |
| **EBL, median (range), (mL)**  | 840 (100–5,600)  | 780 (130–6,100)  | 0.519   |
| **Intraoperative transfusion of packed RBC, n (%)** | |                   |         |
| 0                              | 20 (21)          | 18 (17)           | 0.759   |
| 1–2 units                      | 61 (64)          | 75 (70)           |         |
| >2 units                       | 9 (9)            | 11 (10)           |         |
| 25 (26)                        |                   |                   |         |
| **Postoperative complications, n (%)<sup>a</sup>** | |                   |         |
| Grade 1–3a                     | 20 (21)          | 18 (17)           | 0.759   |
| Grade 3b–4                     | 4 (4)            | 5 (5)             |         |
| Postoperative hospital stay, median (range), (days) | 17 (9–67) | 11 (8–49) | <0.001 |
| Duration from surgery to start of postoperative chemotherapy, median (range), (days) | 35 (15–90)<sup>d</sup> | 33 (12–77)<sup>e</sup> | 0.080 |

MPPE, modified posterior pelvic exenteration; EBL, Estimated blood loss; RBC, red blood cells.
According to the Clavien–Dindo classification [15].

The 1 patient underwent both bowel resections and splenectomy with distal pancreatectomy.

The 2 patients underwent both bowel resections and splenectomy with distal pancreatectomy.

The 3 patients who did not receive postoperative chemotherapy are excluded.

The 5 patients who did not receive postoperative chemotherapy are excluded.

Immediately after surgery, none of the patients required the insertion of a nasogastric tube. Postoperative total parenteral nutrition was not used for any of them. The incidence of anastomotic leakage was similar (1%) in both groups, and these patients received an emergency ileostomy (Fig. 1). Postoperatively, one patient developed ileus because of a small intestinal stenosis at the site of the ileostomy. The mortality rate was zero in both groups. The median time until the start of diet intake was POD 5 (range: 2–8) in the COF group and POD 2 (range: 2–8) in the EOF group ($P<0.001$). In the COF group, diet intake was started by POD 3 in 37 patients (39%), on POD 4–6 in 33 patients (35%), and on POD $\geq$ 7 in 25 patients (26%). All ten patients with a diverting ileostomy started diet intake on POD 2 or 3. Two patients undergoing a splenectomy with a distal pancreatectomy started diet intake on POD 4 and 6, respectively. On the other hand, in the EOF group, diet intake was started on POD 2 in 92 patients (87%), on POD 3–6 in 10 patients (9%), and on POD $\geq$ 7 in 4 patients (4%). Two of the four patients undergoing a splenectomy with a distal pancreatectomy started diet intake on POD 4, and the others started on POD 8. After oral feeding was started, the diet build-up sequence was acceptable for the patients in both COF and EOF groups except for those with anastomotic leakage or ileus at the site of the ileostomy. The median length of the postoperative hospital stay was 6 days shorter for the EOF group than for the COF group (Table 2). However, the duration from surgery until the start of postoperative chemotherapy was not significantly different in the two groups. Eight patients did not receive postoperative chemotherapy. The reasons for this were as follows: (1) 4 patients had stage IA (ovarian tumor was adherent to the rectum with endometriosis or inflammation) disease; (2) 2 patients had low-grade carcinoma; and (3) 2 patients refused postoperative therapy. Stoma closure was performed in 16 of the 18 patients with a diverting or emergency ileostomy at 1–3 months after the completion of the postoperative chemotherapy (Fig. 1). The remaining two patients were unable to undergo stoma closure because of disease regrowth while receiving postoperative chemotherapy consisting of a combination of paclitaxel and carboplatin.

Discussion

A period of starvation after gastrointestinal surgery during which an intestinal anastomosis has been formed has been a common practice. The rationale for starvation was to prevent postoperative nausea and vomiting and to protect the anastomosis, allowing it time to heal before being stressed by food [11]. ERAS programs incorporate evidence-based practices to minimize perioperative stress, intestinal
dysfunction, iatrogenic infections, and postoperative pain and to promote early mobilization and recovery. Most data supporting ERAS programs have come from colorectal surgery. The key components for ERAS in colorectal surgery are as follows: a thorough preoperative patient history, thoracic epidural anesthesia during open (but not laparoscopic) colonic surgery, the avoidance of fluid overload and hypovolemia, no use of a nasogastric tube, and EOF and mobilization [12]. In the field of gynecologic surgery, some studies have demonstrated that increased ERAS guideline compliance is associated with a decrease in the length of the hospital stay across all patients and a lower risk of complications [14, 15]. In a prospective controlled trial of a COF group (n = 72) versus an EOF group (n = 71) following major abdominal gynecologic surgery, the average length of stay for the COF group was 5.8 days, while that for the EOF group was 4.7 days (P = 0.006) [19]. In this study, 83 patients (58%) had ovarian cancer and 19 patients (13%) received upper abdominal surgery. The proportion of women who underwent rectosigmoid resection was not mentioned. In another prospective controlled trial comparing COF (n = 22) and EOF (n = 18) groups of gynecologic oncology patients undergoing intestinal resection, the average length of stay for the COF group was 9.1 days, while that for the EOF group was 6.9 days (P = 0.022) [14]. In this study, 30 patients (75%) underwent rectosigmoid resection and 15 patients (38%) received upper abdominal surgery. In these two prospective controlled trials, patients in the EOF group were initially given a clear liquid diet on POD 1. If well tolerated, they were then given a regular diet. In reviews of ERAS programs for major abdominal gynecologic surgery, EOF appeared to be safe without increased gastrointestinal morbidities or other postoperative complications. The benefits of this approach include a faster recovery of bowel function, lower rates of infectious complications, a shorter hospital stay, and higher patient satisfaction [20–23].

The current study also demonstrated that EOF was feasible and safe for ovarian cancer patients undergoing rectosigmoid resection with anastomosis as a part of cytoreductive surgery. A long period of postoperative starvation seems to be unnecessary, even after high-complexity surgery. Consequently, EOF was associated with a shorter postoperative hospital stay. The lengths of the hospital stay were longer for both groups in the current series than those reported in previous studies. In our study, forty-seven patients (23%) underwent multiple bowel resections and 117 patients (58%) underwent upper abdominal surgery. Therefore, our operating time was much longer than the operating times in previously reported prospective controlled trials, which averaged about 3 hours. The shortness of operative times might partly explain the intestinal function recovery immediately after cytoreductive surgery. Patients in the EOF group were given only liquids on POD 1 and a semisolid diet on POD 2. Our impression from the current study is that a diet of either clear liquids or semisolid food is not tolerable for most ovarian cancer patients undergoing high-complexity surgery, including both rectosigmoid resection and upper abdominal procedures, on POD 1. A proportion of advanced ovarian cancer patients can tolerate a diet on POD 1. We are planning a trial to investigate the safety and clinical usefulness of providing a postoperative diet on POD 1 for patients undergoing cytoreductive surgery with intermediate SCS. The medical insurance system in Japan fully covered the costs of their hospital stay regardless of the length. This system may influence the relatively longer hospital stays that are typical for patients in Japan. However, a comparison of the length of the hospital stay for patients undergoing rectosigmoid resection with anastomosis
between the COF and EOF groups still showed a significant difference even after accounting for potential biases.

Some studies have shown that diverting stomas have the potential to decrease the frequency of anastomotic leakage in ovarian cancer patients undergoing rectosigmoid resection. Houvenaeghel et al. reported that 59 (20%) of 305 patients who underwent rectosigmoid resection with anastomosis during up-front surgery, interval debulking surgery, or secondary debulking surgery received a diverting stoma, and the overall anastomotic leakage rate was 8% in 9 French cancer centers [24]. Another study analyzed retrospective data from 331 patients with stage II–IV ovarian cancer who underwent colon resection during up-front surgery. Forty-four patients (13%) received a diverting ileostomy, and the overall anastomotic leakage rate was 6% [25]. In the current series, the incidence of anastomotic leakage was relatively low (1%) in both COF and EOF groups. However, it should be noted that the patient selection was limited. A diverting stoma was created for 8% of the patients who underwent rectosigmoid resection with anastomosis. The proportion of the patients who had a diverting stoma in the COF group was higher than that in the EOF group. Since the middle of this study period, we have routinely utilized a TDT after rectosigmoid resection with anastomosis for patients with ovarian cancer [17]. TDT placement can decrease the need for a diverting stoma after rectosigmoid resection with anastomosis. In both the COF and EDF groups, all patients with a diverting ileostomy started diet intake on POD 2 or 3.

Some limitations must be considered when interpreting the data from this study. This was a retrospective, not a randomized, study. However, as the safety and benefits of EOF are apparent, planning a prospective randomized study to evaluate the impact of EOF on the postoperative outcomes, including postoperative hospital stay, following rectosigmoid resection in comparison with that of COF is ethically impossible. Despite this limitation, the use of the same surgical techniques by the same gynecologic oncologists at a single institution, the consecutiveness of the patients, and the consistency of the surgical decisions should reduce the possibility of major biases.

**Conclusion**

EOF provides a significant reduction in the length of the postoperative hospital stay without an increased risk of complications after rectosigmoid resection with anastomosis for the treatment of primary ovarian cancer.

**Declarations**

**Availability of data and materials**

The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

**Acknowledgements**
Funding

The authors have no funding source to disclose for this work.

Authors’ affiliations

Department of Gynecology, Cancer Institute Hospital, 3-8-31 Ariake, Koutou-ku, Tokyo 135-8550, Japan

Authors’ contributions

KK: conception, analysis and interpretation, writing of the manuscript; KO and HK: analysis and supervision; SO, MM, HN, TT, YA and MY: acquisition of data and revision for important intellectual content.

Correspondence author

Correspondence to Kazuyoshi Kato

Present address: Department of Obstetrics and Gynecology, Tokyo Medical University

6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo 160-0023, Japan

Ethics approval and consent to participate

The present study was conducted in accordance with the World Medical Association Declaration of Helsinki and was approved by the Institutional Review Board of the Cancer Institute Hospital.

Consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interests.

References

1. Du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer. 2009;115:1234–44.
2. Shih KK, Chi DS. Maximal cytoreductive effort in epithelial ovarian cancer surgery. J Gynecol Oncol. 2010;21:75–80.

3. Chang SJ, Bristow RE, Ryu HS. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer. Ann Surg Oncol. 2012;19:4059–67.

4. Eisenkop SM, Nalick RH, Teng NN. Modified posterior exenteration for ovarian cancer. Obstet Gynecol. 1991;78:879–85.

5. Bristow RE, del Carmen MG, Kaufman HS, Montz FJ. Radical oophorectomy with primary stapled colorectal anastomosis for resection of locally advanced epithelial ovarian cancer. J Am Coll Surg. 2003;197:565–74.

6. Kato K, Tate S, Nishikimi K, Shozu M. Bladder function after modified posterior exenteration for primary gynecological cancer. Gynecol Oncol. 2013;129:229–33.

7. Kato K, Nishikimi K, Tate S, Kiyokawa T, Shozu M. Histopathologic tumor spreading in primary ovarian cancer with modified posterior exenteration. World J Surg Oncol. 2015;13:230.

8. Richardson DL, Mariani A, Cliby WA. Risk factors for anastomotic leak after recto-sigmoid resection for ovarian cancer. Gynecol Oncol. 2006;103:667–72.

9. Son JH, Kim J, Shim J, Kong TW, Paek J, Chang SJ, Ryu HS. Comparison of posterior rectal dissection techniques during rectosigmoid colon resection as part of cytoreductive surgery in patients with epithelial ovarian cancer: Close rectal dissection versus total mesorectal excision. Gynecol Oncol. 2019;153:362–7.

10. Aletti GD, Santillan A, Eisenhauer EL, Hu J, Aletti G, Podratz KC, et al. A new frontier for quality of care in gynecologic oncology surgery: multiinstitutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model. Gynecol Oncol. 2007;107:99–106.

11. Lewis SJ, Egger M, Sylvester PA, Thomas S. Early Enteral Feeding Versus “Nil by Mouth” After Gastrointestinal Surgery: Systematic Review and Meta-Analysis of Controlled Trial. BMJ. 2001;323:773–6.

12. Kehlet H. Fast-track colorectal surgery. Lancet. 2008;371:791–3.

13. Basse L, Hjort Jakobsen D, Billesbølle P, Werner M, Kehlet H. A Clinical Pathway to Accelerate Recovery After Colonic Resection. Ann Surg. 2000;232:51–7.

14. Minig L, Biffi R, Zanagnolo V, Attanasio A, Beltrami C, Bocciolone L, et al. Early oral versus “traditional” postoperative feeding in gynecologic oncology patients undergoing intestinal resection: a randomized controlled trial. Ann Surg Oncol. 2009;16:1660–8.

15. Wijk L, Udumyan R, Pache B, Altman AD, Williams LL, Elias KM, et al. International validation of Enhanced Recovery After Surgery Society guidelines on enhanced recovery for gynecologic surgery. Am J Obstet Gynecol. 2019;221:237. e1–11.

16. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.
17. Kato K, Omatsu K, Matoda M, Nomura H, Okamoto S, Kanao H, et al. Efficacy of transanal drainage tube placement after modified posterior pelvic exenteration for primary ovarian cancer. Int J Gynecol Cancer. 2018;28:220–5.

18. Kato K, Tate S, Nishikimi K, Shozu M. Management of pancreatic fistulas after a splenectomy as part of cytoreductive surgery for ovarian cancer. Int J Gynecol Cancer. 2013;23:1506–11.

19. Minig L, Biffi R, Zanagnolo V, Attanasio A, Beltrami C, Bocciolone L, et al. Reduction of postoperative complication rate with the use of early oral feeding in gynecologic oncologic patients undergoing a major surgery: a randomized controlled trial. Ann Surg Oncol. 2009;16:3101–10.

20. Charoenkwan K, Matovinovic E. Early versus delayed oral fluids and food for reducing complications after major abdominal gynaecologic surgery. Cochrane Database Syst Rev. 2014;2014:CD004508.

21. Miralpeix E, Nick AM, Meyer LA, Cata J, Lasala J, Mena GE, et al. A call for new standard of care in perioperative gynecologic oncology practice: Impact of enhanced recovery after surgery (ERAS) programs. Gynecol Oncol. 2016;141:371–8.

22. Nelson G, Altman AD, Nick A, Meyer LA, Ramirez PT, Achtari C, et al. Guidelines for pre- and intraoperative care in gynecologic/oncology surgery: Enhanced Recovery After Surgery (ERAS®) Society recommendations—Part I. Gynecol Oncol. 2016;140:313–22.

23. Nelson G, Altman AD, Nick A, Meyer LA, Ramirez PT, Achtari C, et al. Guidelines for postoperative care in gynecologic/oncology surgery: Enhanced Recovery After Surgery (ERAS®) Society recommendations—Part II. Gynecol Oncol. 2016;140:323–32.

24. Houvenaeghel G, Gutowski M, Buttarelli M, Cuisenier J, Narducci F, Dalle C, et al. Modified posterior pelvic exenteration for ovarian cancer. Int J Gynecol Cancer. 2009;19:968–73.

25. Tseng JH, Suidan RS, Zivanovic O, Gardner GJ, Sonoda Y, Levine DA, et al. Diverting ileostomy during primary debulking surgery for ovarian cancer: Associated factors and postoperative outcomes. Gynecol Oncol. 2016;142:217–24.